Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Hancock

Anesthesiology Concord, NC Medical Doctor

NPI 1386702066 CMS profile 62315

920 Church St N, Concord, NC 28025

Open in the dashboard

General payments

$5,476

120 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Hancock of Concord, NC is reported in the CMS Open Payments database as having received $5,476 across 120 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $609 12
2024 General $588 15
2023 General $1,928 26
2022 General $704 15
2021 General $253 3
2020 General $203 3
2019 General $1,190 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Hancock
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to James Hancock were reported at $609. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year James Hancock Anesthesiology median Middle half National median
2019 $1,190 $72 $23–$151 $163
2020 $203 $36 $17–$120 $114
2021 $253 $49 $21–$135 $132
2022 $704 $52 $22–$144 $149
2023 $1,928 $53 $23–$143 $160
2024 $588 $55 $25–$150 $164
2025 $609 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,303 32 payments
  2. Medtronic, Inc. $1,162 24 payments
  3. Abbott Laboratories $664 17 payments
  4. Medtronic USA, Inc. $496 10 payments
  5. Relievant Medsystems, Inc. $206 4 payments
  6. Collegium Pharmaceutical, Inc. $130 9 payments
  7. SPR Therapeutics, Inc $128 2 payments
  8. Pfizer Inc. $87 7 payments
  9. Flexion Therapeutics, Inc. $72 4 payments
  10. TerSera Therapeutics LLC $48 2 payments
  11. Other $179 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,512 108 payments
  2. Travel and Lodging $961 11 payments
  3. Education $3 1 payment
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $563 10 payments
  2. INTELLIS ADAPTIVESTIM $507 12 payments
  3. PROCLAIM $402 10 payments
  4. General - Pain Management $316 3 payments
  5. KYPHON EXPRESS II KYPHOPAK TRAY $262 4 payments
  6. SPECTRA WAVEWRITER $242 2 payments
  7. Proclaim Family of SCS IPGs $224 5 payments
  8. INTELLIS $222 4 payments
  9. Intracept $206 4 payments
  10. SYNCHROMEDII $197 5 payments
  11. Other $2,046 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,034

Median for Anesthesiology: 322

Drug cost

$130,346

Median for Anesthesiology: $8,738

Branded share of claims

33.4%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucynta Er Tapentadol Hcl Brand 23 $38,670
Oxycontin Oxycodone Hcl Brand 18 $19,259
Xtampza Er Oxycodone Myristate Brand 25 $17,025
Movantik Naloxegol Oxalate Brand 21 $9,537
Fentanyl Generic 49 $7,603
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 266 $7,055
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 212 $6,827
Oxycodone Hcl Generic 225 $4,723
Gabapentin Generic 268 $4,067
Morphine Sulfate Er Morphine Sulfate Brand 115 $3,853

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$105,242

Medicare's payments for the services billed

Medicare patients

334

Average age 72

Services billed

1,241

198 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 40%
Depression 39%
Diabetes 38%
Chronic kidney disease 33%
Heart failure 26%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

120 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record